ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Inflammation Disrupts Memory - What Can You Do to Protect Your Brain?

All About Ginkgo Biloba: Benefits of This Timeless Herbal Supplement

Yarrow Oil: Here's Why It Deserves a Place in Your First-Aid Kit

Artificial sweeteners linked to risk of weight gain, heart disease and other health issues

Vitamin D supplement use associated with lower risk of breast cancer

Carnitine deficiency suggested as contributor to autism

Hop Oil: A Safe Sleep Aide

Lutein — An Important Nutrient for Eye and Brain Health

White Camphor Oil: The Purest Camphor Oil

Taurine: Facts About This Crucial Amino Acid

 
Print Page
Email Article

Tests Results Promising for New Class of Osteoarthritis Drug

  [ 53 votes ]   [ Discuss This Article ]
www.ProHealth.com • January 10, 2001


A new class of anti-inflammatory agent, the COX/LO inhibitor, had successful and safe results in two recent phase II clinical trials. The compound known as ML3000 is being developed as a treatment for osteoarthritis in the United States.

ML3000, an anti-inflammatory, works by inhibiting the enzymes cyclooxygenase (COX) and 5-lipoxygenase (LOL), hence the name COX/LO inhibitor. Several studies have demonstrated that the anti-inflammatory and pain-relieving abilities of the agent in osteoarthritis (OA) sufferers is comparable to conventional NSAIDs (Non-steroidal anti-inflammatory drugs) and Cox-2 inhibitors.

An additional benefit of this new type of drug is that the usual levels of gastrointestinal side-effects associated with traditional Cox-2 inhibitors were not experienced in the studies. The main side-effects noted with ML300 were diarrhea and abdominal pain.

According to a report in Business Wire, ML3000 is unique because it allows for a well-balanced inhibition of both key enzymes involved in the inflammatory process – Cox and LO. This is important, the report explains, since ML3000 inhibits both Cox-1 and Cox-2 non-selectively, yet is then able to accommodate the body’s physiologic reaction to Cox inhibition. This reaction is to shunt over to the LO pathway of the arachidonic acid cascade. ML3000 blocks the effects of this shunt by additionally blocking LO.

This shunt protection is a vital factor in the way that ML3000 works. LO stimulates the production of a substance called leukotriene, which is the cause of GI damage. When LO is inhibited, leukotriene production is also inhibited, resulting in a decreased risk of GI damage.

In the first study, 107 patients with OA received either ML300 at various doses or placebo for four weeks. Participants receiving ML3000 reported a decrease in the severity of their OA symptoms.

In a second study, 404 OA patients received either ML3000, diclofenac (a type of NSAID) or placebo for four weeks. The OA patients experienced an improvement in pain and mobility, compared to those who were given placebo. The scores were the same for the ML3000 and diclofenac group.

Merckle, a pharmaceutical company, discovered ML3000 and is partnering with Forest Laboratories for the licensing and development of the drug. A spokesman for Forest labs said, “New treatments to manage osteoarthritis are needed because there are many patients who are not adequately treated with the available current medications.” The new partnership will enable phase III testing to go ahead, which the company hopes “might well demonstrate that COX/LO inhibition will result in new pharmaceuticals better suited to the needs of patients than such drugs as the recently introduced COX-2 inhibitors.”

Osteoarthritis is a degenerative joint disease affecting more than 16 million Americans and is the most common form of arthritis.



Post a Comment

Featured Products From the ProHealth Store
Optimized Curcumin Longvida® Energy NADH™ 12.5mg Ultra EPA  - Fish Oil


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health

Natural Remedies

Coping When Colds or Flu Catch Up with You Coping When Colds or Flu Catch Up with You
Clinically Studied Joint Relief Product for FM & ME/CFS Clinically Studied Joint Relief Product for FM & ME/CFS
SAD? Coping with Seasonal Affective Disorder SAD? Coping with Seasonal Affective Disorder
Joint Aches May Have Met Their Match in Curcumin Joint Aches May Have Met Their Match in Curcumin
Three-Step Strategy to Reverse Mitochondrial Aging Three-Step Strategy to Reverse Mitochondrial Aging

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map